Trial Profile
A Phase Ib/II Study of PDR001 Plus Imatinib for Metastatic or Unresectable GIST With Prior Failure of Imatinib, Sunitinib and Regorafenib
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Spartalizumab (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions; Therapeutic Use
- 30 Dec 2022 Status changed from recruiting to completed.
- 22 Jun 2021 Planned End Date changed from 30 Aug 2020 to 30 Aug 2022.
- 22 Jun 2021 Planned primary completion date changed from 30 Aug 2020 to 30 Aug 2022.